Please login to the form below

Not currently logged in
Email:
Password:

Hanspeter Spek to retire from Sanofi

President of global operations will step down after 18 years at the pharma company

Hanspete Spek, SanofiSanofi's president of global oepraitons Hanspeter Spek is to retire.

His will step down in mid-2013 following 18 years service at the company he joined in 1985 as marketing director at Sanofi Pharma GmbH Germany.

Spek rose through the ranks , eventually being appointed to this current position in November, 2009.

“During his many years with Sanofi, Hanspeter has made an exceptional contribution to the success of the group and has helped bring Sanofi to the forefront of the industry,” said the company's CEO Christopher Viehbacher.

“His early recognition of growing opportunities in the emerging markets has contributed to the building of Sanofi's leading position there.”

During his time at Sanofi, he has helped with the success of several significant products, including bloodthinner Plavix, insulin Lantus and cancer drug Taxotere.

A succession plan is to be announced said Sanofi.

21st December 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics